'Pharma bro' Martin Shkreli, the disgraced pharmaceutical executive serving seven years in prison for securities fraud, has been moved to solitary confinement at the Federal Correctional Institution in Fort Dix, New Jersey, according to a report in Forbes.

Shkreli's confinement comes following a Wall Street Journal report that he was using a contraband cell phone to run his business from behind bars.

The Bureau of Prisons would not confirm whether Shkreli had been placed in solitary confinement, saying they do not release information about an "individual inmate's conditions of confinement." The Bureau did confirm they were investigating the allegations made in the Journal's report about Shkreli.

"When there are allegations of misconduct, they are thoroughly investigated, and appropriate action is taken if allegations are sustained," a spokesperson for the BOP said.

The report in the Wall Street Journal alleged that Shkreli was still involved with his business, "Phoenixus AG" using a cellphone that had been smuggled into the prison. Shkreli even fired the firm's interim CEO over the phone, though he did allow him to stay on the company's board.

Possessing a cell phone while in federal custody is a "greatest security level" prohibited act, according the BOP's rules.

One source tells Forbes that Shkreli was moved to the special housing unit (SHU) a week and a half after the article was published on March 7. Shkreli was previously housed in a 12-man cell at a low-security prison in Burlington County. Shkreli became a controversial figure after his compnay increased the prices of rare drugs, angering physicians and patients alike.

Photo: Getty Images